Alvarez-Trotta, A., Wang, Z., Shersher, E., Li, B., Long, J., Lohse, I., . . . Capobianco, A. J. (2020). The bromodomain inhibitor IBET-151 attenuates vismodegib-resistant esophageal adenocarcinoma growth through reduction of GLI signaling. Oncotarget.
Chicago Style aipamenaAlvarez-Trotta, Annamil, et al. "The Bromodomain Inhibitor IBET-151 Attenuates Vismodegib-resistant Esophageal Adenocarcinoma Growth Through Reduction of GLI Signaling." Oncotarget 2020.
MLA aipamenaAlvarez-Trotta, Annamil, et al. "The Bromodomain Inhibitor IBET-151 Attenuates Vismodegib-resistant Esophageal Adenocarcinoma Growth Through Reduction of GLI Signaling." Oncotarget 2020.
Kontuz: berrikusi erreferentzia hauek erabili aurretik.